Royce & Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Royce & Associates’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q2	$1.02M	Buy	32,504 +7,922	+32%	+$250K	0.01%	667
2025 Q1	$805K	Buy	24,582 +11,644	+90%	+$381K	0.01%	696
2024 Q4	$468K	Buy	+12,938	New	+$468K	﹤0.01%	768
2023 Q4	–	Sell	-18,750	Closed	-$517K	–	938
2023 Q3	$517K	Buy	+18,750	New	+$517K	0.01%	808
2023 Q2	–	Sell	-43,619	Closed	-$1.58M	–	965
2023 Q1	$1.58M	Sell	43,619 -184	-0.4%	-$6.67K	0.02%	703
2022 Q4	$1.56M	Sell	43,803 -932	-2%	-$33.2K	0.02%	685
2022 Q3	$1.51M	Sell	44,735 -156	-0.3%	-$5.28K	0.02%	668
2022 Q2	$1.3M	Sell	44,891 -8,919	-17%	-$258K	0.01%	717
2022 Q1	$1.74M	Sell	53,810 -204,314	-79%	-$6.6M	0.01%	739
2021 Q4	$7.53M	Sell	258,124 -113,201	-30%	-$3.3M	0.06%	464
2021 Q3	$9.9M	Buy	371,325 +4,430	+1%	+$118K	0.07%	413
2021 Q2	$11.3M	Sell	366,895 -9,504	-3%	-$293K	0.08%	403
2021 Q1	$9.85M	Sell	376,399 -10,832	-3%	-$284K	0.07%	449
2020 Q4	$9.74M	Buy	387,231 +89,053	+30%	+$2.24M	0.08%	376
2020 Q3	$6.21M	Buy	298,178 +51,149	+21%	+$1.07M	0.07%	425
2020 Q2	$5.87M	Buy	247,029 +14,027	+6%	+$333K	0.06%	416
2020 Q1	$4.19M	Sell	233,002 -16,500	-7%	-$297K	0.06%	421
2019 Q4	$5.92M	Buy	249,502 +32,093	+15%	+$761K	0.05%	448
2019 Q3	$5.97M	Buy	217,409 +203,189	+1,429%	+$5.58M	0.06%	443
2019 Q2	$471K	Buy	14,220 +6,318	+80%	+$209K	﹤0.01%	916
2019 Q1	$277K	Buy	+7,902	New	+$277K	﹤0.01%	979
2018 Q3	–	Sell	-58,000	Closed	-$3.47M	–	1221
2018 Q2	$3.47M	Sell	58,000 -9,000	-13%	-$539K	0.02%	696
2018 Q1	$3.07M	Sell	67,000 -32,000	-32%	-$1.47M	0.02%	728
2017 Q4	$3.95M	Sell	99,000 -60,000	-38%	-$2.39M	0.03%	660
2017 Q3	$6.36M	Hold	159,000	–	–	0.04%	511
2017 Q2	$6.85M	Buy	159,000 +29,000	+22%	+$1.25M	0.05%	492
2017 Q1	$4.07M	Buy	+130,000	New	+$4.07M	0.03%	645